Role of favipiravir in the treatment of COVID-19

Abstract

Highlights Favipiravir is approved by some countries, including India, for COVID-19 treatment. Favipiravir has shown rapid viral clearance and faster clinical improvement. Various treatment recommendations include favipiravir for COVID-19 treatment. Several ongoing clinical trials will further substantiate favipiravir role.

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia

“…Although inhalation of favipiravir and ciclesonide is currently being used to treat coronavirus disease 2019 (COVID- 19) infection, these treatments have not shown convincing efficacy in severe cases. 1,2 In COVID-19 pneumonia, a cytokine storm resulting from an excessive inflammatory response to the viral infection is thought to play a pivotal role in the exacerbation of the pneumonia and its prognosis. 3 Favipiravir and ciclesonide are not effective in the inhibition of the cytokine storm.…”

Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic

“…An additional two favipiravir clinical trials registered under the United States National Library of Medicine clinical trials registry have been completed ( Table 2 ). Several favipiravir phase III clinical trials are ongoing with results expected in December 2020 [ 64 ].…”

COVID-19: One year together

“…Фаворитами в разработке препаратов прямого действия стали ремдесевир -препарат, разработанный против лихорадки эбола, и фавипиравир -препарат второго ряда против гриппа, разработанный в Японии. Производство фавипиравира было начато в России, и в клинических исследованиях, выполненных в разных странах, препарат показал эффективность при применении на ранних сроках заболевания [13]. Ремдесевир оказался неэффективен в исследовании Solidarity под эгидой ВОЗ и не был рекомендован у больных с пневмонией, однако в другом вполне достоверном исследовании снижал летальность в два раза и срок госпитализации в полтора раза [14].…”